AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board

Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board. With over 20 years of experience in pharmaceutical development, Dr. Jain most recently was Senior Vice President and Chief Medical Officer at […]

AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of […]

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

Juliane Bernholz has joined as Chief Operating Officer Kristie Bass has joined as VP Clinical Operations Bunnik, The Netherlands, 1 October 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today […]